NewAmsterdam Pharma Company NV Total Liabilities

The latest total liabilities for NAMS is $73M as of June 2026. That compares with $37M in the prior-year period — up 99.5% year over year. Investors often review this figure alongside NewAmsterdam Pharma Company NV's historical trend and sector peers before judging valuation or financial health.

Over the past year, NAMS's total liabilities moved from $37M to $73M — a 99.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NewAmsterdam Pharma Company NV's operating scale or balance-sheet position.

A total liabilities figure of $73M for NAMS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NAMS's total liabilities ($73M), review year-over-year change from $37M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.